VXRT:OTCMKTS
Vaxart
0,77 USD
arrow_upward
+1,82%(+0,014) 1G
30 apr, 16:00:00 GMT-4 · USD
search
Tutti i simboli
1G
5G
1M
6M
YTD
1A
5A
MAX
| Simbolo | Prezzo | Cambio | % di cambio |
|---|
insights_autoGenerazione degli approfondimenti principali per VXRT in corso…
Apri
0,74 USD
Alto
0,78 USD
Basso
0,74 USD
Cap. mercato
184,37 Mln
Vol. medio
458,71K
Volume
562,36K
Rapporto P/E
10,86
Max 52 sett.
0,84 USD
Min 52 sett.
0,26 USD
Utili per azione
0,07 USD
Beta
1,31
Azioni in circolazione
241,41 Mln
N. di dipendenti
65
Articoli giornalistici
Da fonti sul web
Stock Titan
·
13 ore fa
Vaxart (OTCQX: VXRT) outlines 2025 governance, pay and ownership
Profilo
Vaxart, Inc. is an American biotechnology company focused on the discovery, development, and commercialization of oral recombinant vaccines administered using temperature-stable tablets that can be stored and shipped without refrigeration, eliminating the need for needle injection. Its development programs for oral vaccine delivery include prophylactic, enteric-coated tablet vaccines for inhibiting norovirus, seasonal influenza, respiratory syncytial virus, and human papillomavirus. It was founded in 2004 by Sean Tucker. Originally incorporated as West Coast Biologicals, Inc. in California in 2004, the company later changed its name to Vaxart, Inc. in July 2007, after reincorporating in Delaware. A significant development in the company's history was the reverse merger with Aviragen Therapeutics, Inc. on February 13, 2018, which led to Vaxart becoming a wholly owned subsidiary of Aviragen. Post-merger, the company continued as Vaxart, Inc.
Vaxart's development portfolio includes a range of oral vaccines targeting infectious diseases such as norovirus, COVID-19, and seasonal influenza, as well as therapeutic vaccines like those targeting HPV. Wikipedia
Informazioni su Vaxart
CEO-
Dipendenti65
Data di fondazionemar 2004
SedeSouth San Francisco, California, Stati Uniti
Settore-
Sito webvaxart.com
I contenuti creati con l'AI potrebbero contenere errori. Scopri di più